Video

Q&A with Seth Karol, MD: Risk Factors for Bone Toxicity for Patients with ALL

Author(s):

Seth Karol, MD, St. Jude's Children's Research Center discussed several ways in which he and his colleagues intensified therapy over the years and referred to a key toxicity that had emerged from the two drugs they used.

Seth Karol, MD, St. Jude's Children's Research Center discussed several ways in which he and his colleagues intensified therapy over the years and referred to a key toxicity that had emerged from the two drugs they used.

Karol understands further studies are necessary to ensure their methods of reducing risks don't affect the success of curing diseases.

Related Videos
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
A. Sidney Barritt, MD | Credit: UNC School of Medicine
Muthiah Vaduganathan, MD, MPH | Credit: Brigham and Women's Hospital
© 2024 MJH Life Sciences

All rights reserved.